Welcome to our updated website. Building on the outstanding success of the CSF we are evolving our services across the wider range of immune medicated inflammatory diseases with our new site. Don't forget to bookmark this page!

Over the coming months we will add in new disease areas and you will be able to choose and filter the content that is of most interest to you. For now we have updated our website to allow us to expand and you will see some new layouts and features. Please explore and let us know what you think.

Our offering has not changed: we provide unique educational materials, all for free. Thank you once again for your continued support and feedback across the years. We hope you enjoy the new website.

The Immune Mediated Inflammatory Disease Forum Team

About the Immune-Mediated Inflammatory Disease Forum

The Immune-Mediated Inflammatory Disease Forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in immune-mediated inflammatory diseases. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of inflammatory diseases, and its implications for clinical practice.

The Forum’s programmes are free from commercial bias and feature leading experts sharing their knowledge and experience in the form of video tutorials. Membership of the Forum is free to everyone. Register as a member and have unlimited free access to all of the materials contained within the site.

Choose your Speciality

Filter content quickly by selecting a speciality





Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry


Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized Phase 2 trial


Guselkumab provides durable improvement across psoriatic arthritis disease domains: Post hoc analysis of a Phase 3, randomised, double-blind, placebo-controlled study


Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the Phase 3 KEEPsAKE1 randomized clinical trial

Membership of the Forum is free to everyone.

Register as a member and keep up to date with unlimited free access to all of the material contained within the site.

Register for
FREE now!